Abstracts Archive - Page 117 of 2425 - ACR Meeting Abstracts

Abstract Number: 1013 • ACR Convergence 2024
Burden of Emergency Department Visits and Their Outcomes Among Patients with Rheumatoid Arthritis: Insights from the Nationwide Emergency Department Sample (NEDS)
Vishwesh Bharadiya¹, Aman Singh², Parul Berry¹, Dominique Feterman Jimenez³, Grant Hughes³, Alison Bays³, Rachael Stovall³, Rashmi Dhital⁴ and Namrata Singh⁵, ¹AIIMS, New Delhi, India, ²Rajindra Hospital, Patiala, Punjab, India, ³University of Washington, Seattle, WA, ⁴UC San Diego, Brentwood, TN, ⁵University of Washington, Bellevue, WA
Background/Purpose: Patients with rheumatoid arthritis (RA) frequently visit the emergency department (ED). However, very little is known regarding the clinical characteristics of patients visiting the…
Abstract Number: 1472 • ACR Convergence 2024
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Natalie J. Shiff⁴, Anthony Todd⁵, Emmanouil Rampakakis⁶, Francois Nantel⁷, Jenna Parrett⁵, Frederic Lavie⁸ and Proton Rahman⁹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ³University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷Nantel Medsci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated multidomain efficacy (swollen/tender joints, psoriasis, enthesitis and dactylitis) in patients (pts) with active PsA in…
Abstract Number: 1473 • ACR Convergence 2024
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
M. Elaine Husni¹, Philip Mease², Dafna Gladman³, Barbara Ink⁴, Jérémy Lambert⁵, Patrick Healy⁶ and Laure Gossec⁷, ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Colombes, France, ⁶UCB Pharma, Morrisville, NC, ⁷Sorbonne Université, Paris, France
Background/Purpose: PsA is characterized by joint and skin inflammation, and associated with debilitating symptoms of pain and fatigue.1 Previous research has shown that pain and…
Abstract Number: 1409 • ACR Convergence 2024
Salivary Organoids Contain More Diverse Epithelial and Less Mesenchymal Cells Than Adherent Cultures: Choose Your Sjögren’s Disease Research Tool Carefully
Ting Yang¹, Abel Soto Gamez¹, Janneke Terpstra¹, Hendrika Bootsma², Arjan Vissink¹, Frans Kroese³ and Sarah Pringle³, ¹UMCG, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: The majority of the critical pieces of work probing the involvement of the salivary gland (SG) epithelium in Sjogren’s Disease (SjD) employ salivary gland…
Abstract Number: 1284 • ACR Convergence 2024
Unlocking Insights into Juvenile Dermatomyositis: Clinical and Demographic Profiles Paired with Total Improvement Scores at a Tertiary Center
keerthivardhan yerram¹, phanikumar devarasetti¹ and Liza Rajasekhar², ¹Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disorder that predominantly affects the skin and muscles in children under the age of sixteen. Literature on…
Abstract Number: 1390 • ACR Convergence 2024
One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)
Luis Gomez-Lechon Quiros¹, José Miguel Sequí-Sabater², Amalia Rueda³, Costas Torrijo Nerea⁴, Carlos Valera-Ribera⁵, Juan Miguel López-Gómez⁶ and Antonio Alvarez-Cienfuegos⁷, ¹Hospital Francesc de Borja, Valéncia, Spain, ²La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, ³Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ⁴Generalitat valenciana, Valencia, Spain, ⁵Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, ⁶Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, ⁷Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
Abstract Number: 1481 • ACR Convergence 2024
Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials
Atul Deodhar¹, Iain McInnes², Xenofon Baraliakos³, Alice Gottlieb⁴, Uta Kiltz⁵, Stefan Schreiber⁶, Braja Gopal Sahoo⁷, Weibin Bao⁸, Corine Gaillez⁹, Mercedes Bustamante⁹ and Philip Mease¹⁰, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ³Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ⁴Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁶University Hospital Schleswig-Holstein, Kiel, Germany, Kiel, Germany, ⁷Novartis Healthcare Private Limited, Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Secukinumab, a fully human anti-interleukin (IL)-17A monoclonal antibody, is approved for multiple immunological disorders, including moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA), axial spondyloarthritis…
Abstract Number: 1496 • ACR Convergence 2024
Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Loqmane seridi¹, Steven Leonardo², Brittney Scott³, Robert Gordon¹, cathye shu¹, Kaiyin Fei¹, Kim Lo³, Anne Stevens¹ and Sheng Gao³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA
Background/Purpose: SLE is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients with specific clinical manifestations…
Abstract Number: 1449 • ACR Convergence 2024
Evaluating Spine Structural Damage on a Single CT in Patients with Ankylosing Spondylitis, and According to the Presence of Skin Psoriasis
Andrea MENNINI¹, Damien Loeuille², Isabelle Chary-Valckenaere³, Caroline Morizot⁴ and Marie LAFFAIRE¹, ¹CHRU Nancy, Nancy, France, ²Phd, Nancy Vandoeuvre, Lorraine, France, ³Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, ⁴Nancy University hospital, Nancy, France
Background/Purpose: To compare, on Thoraco-Abdomino-Pelvic (TAP) computed tomography (CT), structural spinal involvement of the dorsal and lumbar segments in ankylosing spondylitis with (AS-Pso) and without…
Abstract Number: 1419 • ACR Convergence 2024
Antiphospholipid Antibodies and Hypercoagulable Events in Patients with Sjogren’s Syndrome
Katelyn Kaufman¹ and Schartess Culpepper Pace², ¹University of Miami Holy Cross Hospital, Fort Lauderdale, FL, ²University of Miami, Pembroke Pines, FL
Background/Purpose: The association between antiphospholipid antibodies (aPL) and autoimmune processes, such as systemic lupus erythematosus (SLE) is well documented, however, there are limited data on…
Abstract Number: 1294 • ACR Convergence 2024
Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis
Bharati Hegde, Jillian Scavone, Katie Robinson and Robert Esgro, Vindico Medical Education, West Deptford, NJ
Background/Purpose: Given the rarity and non-specific symptoms associated with ANCA-associated vasculitis (AAV), rheumatology clinicians are challenged to use best practices for patient recognition and management,…
Abstract Number: 1393 • ACR Convergence 2024
Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
Roy Fleischmann¹, Zoltán Szekanecz², Eduardo Mysler³, Kevin Winthrop⁴, Kunihiro Yamaoka⁵, Kirsten Famulla⁶, Yanna Song⁷, Birgit Kovacs⁷, Sander Strengholt⁸ and Gerd Burmester⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Debrecen, Debrecen, Hungary, ³Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ⁴School of Medicine, Oregon Health and Science University, Portland, OR, ⁵Kitasato University School of Medicine, Sagamihara, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁷AbbVie, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Patients with RA are at a heightened risk of developing significant adverse events (AEs) such as MACE, VTE, and serious infectious events (SIE). Limited…
Abstract Number: 1040 • ACR Convergence 2024
Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics
Jasvinder Singh¹, Larry Hearld², Walter Chatham³, Sonali Narain⁴, Narender Annapureddy⁵, Diane Kamen⁶, Kimberly Trotter⁷, vikas Majithia⁸, Cathy Lee Ching⁹, Zineb Aouhab¹⁰, Swamy Venuturupalli¹¹, Daniel Wallace¹², rosalind Ramsey-Goldman¹³, Alfred Kim¹⁴, Maureen McMahon¹⁵, S. Sam Lim¹⁶, Kalpana Bhairavarasu¹⁷, Alexa Meara¹⁸ and Kenneth Kalunian¹⁹, ¹Baylor College of Medicine, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV, ⁴Northwell Health, Great Neck, NY, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Chicago, Chicago, IL, ⁸University of Missisippi Medical Center (UMC), Jackson, MS, ⁹UMMC, Jackson, MS, ¹⁰Loyola University Medical Center, Oak Brook, IL, ¹¹Attune Health, Beverly Hills, CA, ¹²Cedars Sinai Medical Center, Studio City, CA, ¹³Northwestern University, Chicago, IL, ¹⁴Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁵UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁶Emory University, Atlanta, GA, ¹⁷Baylor College of Medicine, Sugar Land, TX, ¹⁸The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁹University of California San Diego, La Jolla, CA
Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
Abstract Number: 1455 • ACR Convergence 2024
Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
Fadi Kharouf¹, Shangyi Gao², Ali Alhadri², Daniel Pereira³, Richard Cook⁴, Vinod Chandran⁵ and Dafna Gladman⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Secondary failure to biologic therapy is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). In this study, we aimed to define…
Abstract Number: 1500 • ACR Convergence 2024
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres
Behdin Nowrouzi-Kia¹, J. Antonio Avina-Zubieta², Mary Fox³, William Shaw⁴, Maggie Ho⁵, Qixuan Li⁵, Catherine Ivory⁶, Paul Fortin⁷, Stephanie Keeling⁸, Jennifer Reynolds⁹, Derek Haaland¹⁰, Janet Pope¹¹, Lily Lim¹², Patti Katz¹³, Murray Urowitz¹⁴, Laura Patricia Whittall Garcia⁵, Dafna Gladman¹⁵ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³York University, Toronto, ON, Canada, ⁴University of Connecticut, School of Medicine, Farmington, CT, ⁵University Health Network, Toronto, ON, Canada, ⁶The Ottawa Hospital, Ottawa, ON, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹UBC, North Vancouver, BC, Canada, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³UCSF, San Rafael, CA, ¹⁴Self employed, Toronto, ON, Canada, ¹⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) has a significant and long-lasting impact on work outcomes, is a source of long-lasting work disability, and presents challenges with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].